Many of the many biotech companies that raised money to develop and repurpose their molecules to address the pandemic have started to unwind those efforts. What will this mean for the sector’s valuation?

A cap set at $2,000 would help nearly 1 million more seniors than a cap set at $3,100, according to new study by Kaiser Family Foundation. Either competing legislative proposal would probably be welcomed by pharma industry as way to defuse pricing debate.

Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.

Taiwan's president the first to receive domestically developed vaccine which results so far suggest has high efficacy, amid multiple challenges for the local inoculation campaign.